Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results
On track to fuel the pipeline with =4 new product candidates in 2021
Strong cash position of €64 million year-end to execute ambitious growth plan
14 commercial products expected by 2024
Conference call and
Liège, Belgium - 9 March 2021 -
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented:
I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our knowhow and innovative technol
Belgium
Australia
United-states
Hong-kong
United-kingdom
Czech-republic
Austria
Leuven
Region-flamande
United-arab-emirates
Slovakia
Abuz-aby